# OnCo record nct06472076 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06472076/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06472076", "NCT06472076" ;
  schema:name "A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)"@en ;
  schema:alternateName "GALAXIES Lung-301"@en ;
  schema:description "A phase 3 trial of Dostarlimab and Pembrolizumab in non-small-cell lung cancer, run by GlaxoSmithKline, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06472076/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06472076> ;
  onco:status "active" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2024-06-10" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/pdl1-high-nsclc/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/dostarlimab/>, <https://onco.cc/drugs/pembrolizumab/> ;
  onco:companies <https://onco.cc/companies/gsk/> .